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A 55-year-old woman with chronic hepatitis C presented with acute painless, unilateral, granulomatous
uveitis without other systemic symptoms. Ocular symptoms began 20 weeks after starting pegylated
interferon alpha (IFN-a)-2a and ribavirin. The anterior granulomatous uveitis quickly improved after
application of topical steroid. However, the vision of the right eye worsened 4 weeks later because of
a new episode of vitritis with multiple snowballs along and in retinal vessels. These were nodular and/or
segmental periphlebitis with candlewax drippings in appearance. Multiple granulomas persisted for 4
weeks and spontaneously disappeared after immediate discontinuation of IFN-a therapy. We reviewed
eight additional granulomatous uveitis of presumed ocular sarcoidosis during IFN-a therapy in previous
articles and all of these patients suffered from bilateral uveitis. However, our case was treated with IFN-a
and resulted in unilateral granulomatous panuveitis. Sixteen weeks after discontinuation of IFN-a
therapy, the patient recovered well with regards to vision and no recurrence occurred.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Several studies have reported that pegylated interferon alpha
(IFN-a)-associated retinopathy in chronic hepatitis C (CHC)
demonstrated symptoms ranging from asymptomatic changes of
superﬁcial retinal hemorrhage to severe retinal vascular occlusion
or retinal detachment [1e10]. This kind of retinopathymay relate to
retinal microvascular disturbance. In adults, 19e29% of IFN-a-
treated CHC cases have developed retinopathy; for IFN-a-treated
CHC cases involving children, ophthalmologic complications
occurred in 2e3% cases [11]. Other ocular complications associated
with IFN-a therapy include transient blurred vision [12], neo-
vascular glaucoma [13], severe orbital and intraocular hemorrhage
[14], progression of existing retinopathy [13,15], and ischemic optic
neuropathy [16e18].
A few articles have reported that ocular inﬂammation, such as
Vogt-Koyanagi-Harada-like disease [8] and sarcoidosis [19e23],
are associated with IFN-a treatment for CHC. IFN-induced ocu-
lar sarcoidosis needs to be differentiated from IFN-inducedlmology, Buddhist Tzu Chi
ualien, Taiwan. Tel.: þ886 3
ddhist Compassion Relief Tzu Chiretinopathy. Typical changes of IFN retinopathy lack vitreous inﬁl-
tration and granulomas in the fundus [19]. We were already aware
of the association between presumed ocular sarcoidosis and IFN
from previous ophthalmological-related literature [19]. Although
ocular sarcoidosis associated with IFN-a have been reported, all of
their cases were bilateral eye changes [19,20]. In our case, presen-
tation of unilateral granulomatous panuveitis with nodular
periphlebitis was seen as a special presentation of IFN-induced
sarcoidosis.
2. Case report
A 55-year-old woman with a history of CHC developed painless
progressive vision loss in her right eye. She had no history of eye
trauma and did not detect visual loss in the left eye. She also noted
intermittent violaceous skin lesions on her forearm without other
systemic problems. Twenty weeks before ophthalmic evaluation,
she began treatment for CHC with pegylated IFN-a-2a, Pegasys
(Roche, Basel, Switzerland) at 180 mg/wk and ribavirin 600 mg/d.
Other medications included omeprazole, cimetidine, folic acid, and
mosapride citrate. Ocular examination revealed best corrected
visual acuity 8/20 in the right eye and 20/20 in the left eye. Pupils
were 3 mm bilateral without relative afferent pupillary defect.
Intraocular pressure was 32 mmHg in the right eye and 14 mmHg
in the left eye. Slit-lamp examination revealed a ciliary injectionFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A and B) Bilateral retinal photography revealed severe vitreous haziness in the right eye compared with the retina of the other eye.
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anterior chamber of the right eye. Fundus examination demon-
strated moderate haziness in the vitreous cavity of the right eye
(Fig. 1). The anterior and posterior segments of the left eye were
normal. The cytology of aqueous and vitreous samples showed no
malignant cells and a vitreous culture was negative for any path-
ogens. A hemogram and comprehensive metabolic panel were
shown to be normal. Erythrocyte sedimentation rate (ESR) was
54 mm/1 hr and serologic test of syphilis/rapid plasma regain (STS-
RPR), antinuclear antibody, anti-ds DNA antibody, rheumatoid
factor, C-reactive protein, Herpes simplex virus immunoglobulin M,
and Varicella zoster virus immunoglobulin Mwere all negative. She
had abnormal liver enzyme tests. A chest scan for hilar lymph-
adenopathy and a tuberculin skin test were both negative.
A unilateral uveitis related to IFN-a was suspected. Because of
the unstable condition of hepatitis C, continued IFN-a therapyFig. 2. (A and B) Retinal photography showed numerous granulomas along and in the retin
Fluorescence angiography showed that ﬂow in the vessels was not blocked by nodular depo
arrow head). There was no classic pattern of retinal vasculitis, such as neovascularization owas planned and the patient was simultaneously treated with
topical prednisolone acetate 1.0% for every 2 hours. Although she
was still on IFN-a treatment, obvious improvement of anterior
uveitis and normal intraocular pressure was noted after 1 week
of topical steroid application. However, persistent vitritis and new
lesions of multiple granulomas in and along her right retinal
vessels (both artery and vein) were noted on retinal photography
and ﬂuorescein angiography (FAG) 4 weeks after the ocular
symptoms began (Fig. 2). There was no vessel leakage, neo-
vascularization, macular edema, hypertrophy, or scar of retinal
pigment epithelium on FAG. Her right visual acuity had decreased
to 6/20. Fortunately, discontinuation of IFN-a therapy induced the
spontaneous improvement of granulomatous panuveitis. Four
months after ceasing IFN-a therapy, multiple granulomas on the
retina completely disappeared and vision returned back to
normal (Fig. 3).al vein (white arrow) and artery (white arrow head) and the cloud vitreous. (C and D)
sits, so-called nodular periphlebitis with candlewax drippings (white arrow and white
r vascular leakage.
Fig. 3. (A) Retinal photography and (B) ﬂuorescence angiography. Four months after IFN-a discontinuing, granulomas on the retina spontaneously disappeared but mild vitreous
opacity still presented. IFN-a¼ interferon alpha.
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Several articles have already reported mechanisms of IFN-a
retinopathy. A study using a rat model demonstrated that IFN-a
causes leukocyte activation as well as abnormally high levels of
circulating activated plasma complement 5 and adherence to
vascular endothelium [24,25]. However, the exact mechanisms of
ocular sarcoidosis associated to IFN-a therapy are still not clear
[6,14,19,20,26].
The adverse general effects of IFN-a treatment in CHC, such as
fatigue, headache, fever, and myalgias, are common [27]. IFN-
induced sarcoidosis seems to cause a lower frequency of pulmonary
involvement and a higher incidence of cutaneous and articular
involvement [23]. Before the causes of unilateral panuveitis can be
determined, we need to consider the causes of autoimmunity,
infection, and malignancy ﬁrst. Importantly, the ﬁnding of granu-
lomatous inﬂammation is usually suggestive of a unique set of
etiologic agents. Causes of granulomatous uveitis are sarcoidosis,
sympathetic ophthalmic, lens-induced uveitis, intraocular foreign
body, Vogt-Koyanagi-Harada syndrome, syphilis, and tuberculosis.
Based on the evidence from our patient and information from
previous case reports, we propose, in our case, that there is
a possible association between IFN-a therapy and ocular sarcoid-
osis [28].
The International Uveitis Study group criteria in 2000 classiﬁed
ocular sarcoidosis into isolated anterior uveitis, intermediate
uveitis, retinal vasculitis with or without panuveitis, and multifocal
choroiditis [29]. The consensus conference in 2009 held by the
International Workshop On Ocular Sarcoidosis identiﬁed seven
signs in the diagnosis of intraocular sarcoidosis: (1) mutton-fat
keratic precipitates (KPs)/small granulomatous KPs and/or iris
nodules (Koeppe/Busacca); (2) trabecular meshwork nodules and/
or tent-shaped peripheral anterior synechiae; (3) vitreous opacities
displaying snowballs/strings of pearls; (4) multiple chorioretinal
peripheral lesions (active and/or atrophic); (5) nodular and/or
segmental periphlebitis (þ/ candlewax drippings) and/or retinal
macroaneurism in an inﬂamed eye; (6) optic disc nodules/granu-
lomas and/or solitary choroidal nodules; and (7) bilaterality [30].
We believe that those nodules in the retina vessels were nodular
and/or segmental periphlebitis with candlewax drippings. There
was no additional typical choriocapillaris leakage, choroidal
inﬂammation, and neovascularization showing on FAG. Classical
focal retinal pigment epithelial cell proliferation, suggestive of
Dalen-Fuchs nodules, shows hypoﬂuorescent in the early phases
and late staining. However, our granulomas were only in and along
the retinal vessels with no staining in the late phase of FAG, and so,
uncharacteristic of Dalen-Fuchs nodules. These white granulomaswere deposits in the retinal vessels and did not cause total
obstruction of blood ﬂow. Our case was panuveitis but did not have
severe retinal vasculitis as well as macular edema so that the
prognosis of vision was good without complications.
In a reviewof Pubmed, eight caseswith uveitis as amanifestation
of IFN-induced sarcoidosiswere reported [19,20,22,23]. The last case
reported by Doycheva et al [19] was comparable to our case with
some similarities, including no increasing angiotensin-converting
enzyme and no pulmonary involvement. Although we did not have
documents of biopsy or angiotensin-converting enzyme titer, our
case diagnosed ocular sarcoidosis because of typical mutton fat KPs.
Acute anterior uveitis with the mutton fat or granulomatous KPs is
highly suggestive of sarcoidosis [30]. Themost important additional
diagnostic clue of unilateral IFN-a-induced ocular sarcoidosis is
good visual prognosis after merely ceasing IFN-a therapy.
In the treatment of ocular sarcoidosis, oral corticosteroids
combined with the discontinuation of IFN-a have been recom-
mended [19,23]. The uveitis in sarcoidosis related to IFN-a therapy
had good visual prognosis [19]. In 46 sarcoidosis cases related to
IFN-a therapy, they found remission in 83%, stabilization in 11%, and
reactivation in 6% of patients [23]. Although the symptoms and
signs of ocular sarcoidosis may ﬂuctuate before the ceasing of IFN-a
therapy, ﬁnally, the visual prognosis was favorable. No recurrence
of granulomatous uveitis was observed during 1 year of follow-up.
In conclusion, CHC treated with IFN-a may lead to the devel-
opment of unilateral ocular sarcoidosis. Completing IFN-a therapy
may not cause irreversible ocular side effects under close follow-up.
Cooperation of ophthalmologists andmedical physicians in cases of
CHC treatment with IFN-a is very important.References
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